Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
PARP inhibitor
DRUG CLASS:
PARP inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
olaparib (342)
talazoparib (81)
niraparib (80)
rucaparib (71)
ABT-888 (35)
pamiparib (18)
fluzoparib (12)
JPI-547 (7)
senaparib (6)
NOV 1401 (3)
SC10914 (2)
ABT-767 (1)
SBP-101 (1)
AMXI-5001 (0)
AZD2461 (0)
E7016 (0)
HWH340 (0)
MK-4837 (0)
TSL1502 (0)
[²¹¹At]PTT (0)
kt-3283 (0)
SMOCL-9112 (0)
2X-121 (0)
olaparib (342)
talazoparib (81)
niraparib (80)
rucaparib (71)
ABT-888 (35)
pamiparib (18)
fluzoparib (12)
JPI-547 (7)
senaparib (6)
NOV 1401 (3)
SC10914 (2)
ABT-767 (1)
SBP-101 (1)
AMXI-5001 (0)
AZD2461 (0)
E7016 (0)
HWH340 (0)
MK-4837 (0)
TSL1502 (0)
[²¹¹At]PTT (0)
kt-3283 (0)
SMOCL-9112 (0)
2X-121 (0)
›
Associations
(715)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA2 mutation
Pancreatic Cancer
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Pancreatic Cancer
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.